Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes
单位:[1]Nanjing First Hospital, Nanjing, China[2]China-Japan Friendship Hospital, Beijing, China[3]Peking University Third Hospital, Beijing, China[4]Tianjin Medical University General Hospital, Tianjin, China[5]Nanjing Medical School, 2nd Affiliated Hospital, Nanjing, China[6]Shanghai First People’s Hospital, Shanghai, China[7]First Affiliated Hospital of Anhui Medical University, Hefei City, China[8]Fuzhou General Hospital of Nanjing Military Command, Nanjing, China[9]The First Affiliated Hospital of Nanjing Medical University, Nanjing, China江苏省人民医院[10]Novo Nordisk, Beijing, China[11]Novo Nordisk, Søborg, Denmark[12]Peking Union Medical College Hospital, Beijing, China.
Ma J.,Yang W.,Hong T.,et al.Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes[J].DIABETOLOGIA.2018,61:S410-S411.
APA:
Ma, J.,Yang, W.,Hong, T.,Liu, M.,Miao, H....&Weigang, Z..(2018).Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes.DIABETOLOGIA,61,
MLA:
Ma, J.,et al."Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes".DIABETOLOGIA 61.(2018):S410-S411